Edition:
United States

Threshold Pharmaceuticals Inc (THLD.O)

THLD.O on Consolidated Issue listed on NASDAQ Capital Market

0.40USD
23 Jun 2017
Change (% chg)

-- (--)
Prev Close
$0.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
759,030
52-wk High
$1.48
52-wk Low
$0.35

Latest Key Developments (Source: Significant Developments)

Threshold Pharma says first patient dosed in clinical trial of evofosfamide, ipilimumab
Tuesday, 13 Jun 2017 08:01am EDT 

June 13 (Reuters) - Threshold Pharmaceuticals Inc ::Threshold Pharmaceuticals announces first patient dosed in immunotherapy clinical trial of evofosfamide and ipilimumab.Threshold Pharmaceuticals Inc - ‍phase 1 clinical trial will evaluate effect of ipilimumab and evofosfamide (TH-302) in advanced solid tumors​.Threshold Pharmaceuticals Inc - ‍immune-related response evaluation criteria in solid tumors (irrecist) response rate is primary endpoint​.  Full Article

OBI Pharma buys TH-3424 from Threshold Pharmaceuticals
Thursday, 1 Jun 2017 05:00am EDT 

June 1 (Reuters) - OBI Pharma Inc <4174.TWO>:OBI Pharma announces acquisition of TH-3424 from Threshold Pharmaceuticals.OBI Pharma says product will be renamed OBI-3424 effective immediately.OBI Pharma - Threshold to transfer to co its ownership rights as well as preclinical,manufacturing data for OBI-3424 for undisclosed, upfront one-time payment.OBI Pharma - plans to accelerate development of OBI-3424, with IND application filing with U.S. FDA planned for early 2018.  Full Article

Threshold Pharmaceuticals files for non-timely 10-Q
Tuesday, 16 May 2017 05:17pm EDT 

May 16 (Reuters) - Threshold Pharmaceuticals Inc :Files for non-timely 10-Q - SEC filing.Threshold Pharmaceuticals says due to connectivity issues with Edgar server, co was unable to file form 10-Q for period ended March 31, 2017.  Full Article

Threshold Pharmaceuticals reports Q1 loss per share of $0.07
Monday, 15 May 2017 04:24pm EDT 

May 15 (Reuters) - Threshold Pharmaceuticals Inc :Threshold Pharmaceuticals reports first quarter financial results.Definitive merger agreement between Threshold and Molecular Templates expected to close mid-2017.Qtrly loss per share $0.07.Initiation of phase 1 clinical trial of Evofosfamide in combination with Ipilumumab on track to start in mid-2017.  Full Article

Threshold Pharmaceuticals posts Q4 loss of $3.7 mln
Monday, 27 Mar 2017 04:01pm EDT 

Threshold Pharmaceuticals Inc : Threshold pharmaceuticals reports fourth quarter and full year 2016 financial results . Threshold pharmaceuticals- no revenue recognized in Q4 and year ended December 31, 2016 compared to $65.9 million and $76.9 million for same periods in 2015 .Threshold pharmaceuticals inc- net loss for Q4 ended December 31, 2016 was $3.7 million compared to net income of $69.7 million for same period in 2015.  Full Article

Threshold Pharmaceuticals and Molecular Templates agree to combine
Friday, 17 Mar 2017 07:17am EDT 

Threshold Pharmaceuticals Inc : Threshold Pharmaceuticals and Molecular Templates agree to combine . Threshold Pharmaceuticals Inc says combined company will be capitalized to support advancement of MT-3724 . Longitude Capital will invest $20 million at close of transaction . Threshold Pharmaceuticals Inc says transaction has been approved by board of directors of both companies . Threshold Pharma - concurrent with execution of merger agreement, Threshold made a bridge loan to Molecular Templates in principal amount of $2 million. . Threshold Pharmaceuticals - Molecular Templates shareholders would own about 65.6 percent of combined company . Threshold - on pro forma basis & based upon number of shares to be issued in deal, current threshold shareholders would own about 34.4 percent of combined co . Threshold Pharmaceuticals - in event that transaction does not close by May 31, 2017, co agreed to make available further funding of up to $2 million . Threshold Pharmaceuticals - Eric Poma, Molecular Templates' chief executive officer, will become Chief Executive Officer of combined company . Threshold Pharmaceuticals - Longitude Capital will invest $20 million including receipt of additional equity financing commitments of $20 million . Threshold Pharmaceuticals - following deal, board of co will consist of seven seats and will be comprised of two representatives of Molecular Templates.  Full Article

First Eagle Investment Management LLC reports 9.91 pct passive stake in Threshold Pharmaceuticals
Monday, 6 Feb 2017 03:31pm EST 

Threshold Pharmaceuticals Inc :First Eagle Investment Management LLC reports a 9.91 percent passive stake in Threshold Pharmaceuticals Inc as on December 31, 2016 - SEC filing.  Full Article

Threshold Pharmaceuticals says to cut about a quarter of its workforce - SEC Filing
Thursday, 29 Sep 2016 05:38pm EDT 

Threshold Pharmaceuticals Inc: Says implementing a workforce reduction constituting approximately a quarter of the company's workforce - SEC Filing . As a result of the workforce reduction, co estimates to record in Q4 a one-time severance-related charge about $0.9 million . Says notified employees affected by the workforce reduction on September 29, 2016 . Says expects to complete the workforce reduction by October 7, 2016 . Threshold pharmaceuticals inc says on September 29, Stewart Kroll, COO, notified that his position would be eliminated as part of workforce reduction .Undertaking workforce reduction to reduce expenses, preserve capital while focusing efforts on studies of Evofosfamide.  Full Article

Threshold Pharmaceuticals Q2 loss per share $0.10
Monday, 1 Aug 2016 08:00am EDT 

Threshold Pharmaceuticals Inc : Q2 revenue $110 million . Threshold Pharmaceuticals reports second quarter financial results . Qtrly loss per share $0.10 .Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.  Full Article

Threshold Pharmaceuticals Inc announces workforce reduction
Friday, 18 Dec 2015 04:17pm EST 

Threshold Pharmaceuticals Inc:Announces workforce reduction.Says will reduce its workforce by approximately two-thirds, resulting in between 20-25 remaining employees.Anticipates one-time severance-related charge associated with workforce reduction to be about $2.6 million.Says the majority of the charges will be paid by the end of the first quarter of 2016.Sees one-time severance-related charge associated with workforce reduction to be about $2.6 million.Enacting reduction in workforce as a result of outcomes from two phase 3 trials of evofosfamide.Says Threshold has a global license and co-development agreement for evofosfamide with Merck KGaA.  Full Article

More From Around the Web

BRIEF-Threshold Pharma says first patient dosed in clinical trial of evofosfamide, ipilimumab

* Threshold Pharmaceuticals announces first patient dosed in immunotherapy clinical trial of evofosfamide and ipilimumab